Taylor Hendon
Family · Nashville, TNNPI 1588019772
Payments from drug & device makers
Across 530 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Mannkind Corporation$2K
- Lilly USA, LLC$1K
- Abbott$1K
- Insulet Corporation$804
- Boehringer Ingelheim$767
- plus $3K from 25 others
What the payments were for
- Food & beverage$10,733100%
- Education$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,812 |
| Mannkind Corporation | 108 | $1,523 |
| Lilly USA, LLC | 64 | $1,407 |
| Abbott | 84 | $1,183 |
| Insulet Corporation | 27 | $804 |
| Boehringer Ingelheim | 35 | $767 |
| Xeris Pharmaceuticals, Inc. | 18 | $382 |
| Medtronic | 12 | $368 |
| Cequr Corporation | 3 | $363 |
| Tandem Diabetes Care, Inc. | 12 | $348 |
| Sanofi-aventis U.S. LLC | 16 | $335 |
| Amgen | 14 | $224 |
| BETA Bionics, Inc. | 11 | $211 |
| Dexcom, Inc. | 5 | $151 |
| Zealand Pharma US, Inc. | 1 | $117 |
| Amneal Pharmaceuticals LLC | 5 | $93 |
| Amphastar Pharmaceuticals, Inc. | 4 | $82 |
| AbbVie | 5 | $78 |
| IBSA Pharma Inc. | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Ascensia Diabetes Care US Inc. | 3 | $70 |
| Corcept Therapeutics | 2 | $52 |
| Nevro Corp. | 2 | $37 |
| Sequel Med Tech, LLC | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Bigfoot Biomedical Inc | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Halozyme Inc | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$330
- Ozempic$231
- Omnipod$230
- t:slim X2 Insulin Pump with Control-IQ$132
- InPen$125
- JARDIANCE$123
- ZEGALOGUE$117
- RYBELSUS$108
How this compares
$10,734 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 747 | $820,270 |
| TrulicityDulaglutide | 309 | $397,937 |
| Tresiba Flextouch U-200Insulin Degludec | 353 | $380,376 |
| MounjaroTirzepatide | 257 | $304,587 |
| JardianceEmpagliflozin | 331 | $302,138 |
| FarxigaDapagliflozin Propanediol | 166 | $155,384 |
| Tresiba Flextouch U-100Insulin Degludec | 344 | $123,785 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 102 | $77,239 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $40,998 |
| Novolog FlexpenInsulin Aspart | 160 | $36,330 |
| Humalog Kwikpen U-100Insulin Lispro | 141 | $30,039 |
| GlyxambiEmpagliflozin/Linagliptin | 19 | $26,419 |
| TradjentaLinagliptin | 29 | $26,395 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $20,151 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 43 | $19,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,812 | $824,223758 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,407 | $712,573602 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr | $767 | $371,754390 claims |
| AstraZenecaFarxiga | $17 | $155,384166 claims |
| Sanofi-aventis U.S. LLCLantus | $335 | $1,36813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Nashville
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.